Treatment for multiple myeloma: pharmacoeconomic aspects

DOI: https://doi.org/10.29296/25419218-2021-04-02
Issue: 
4
Year: 
2021

Yu.A. Zabolotneva, K.G. Gurevich, A.V. Zaborovsky, L.V. Tararina A.I. Evdokinov Moscow State University of Medicine and Dentistry, 20, Delegatskaya St., Build. 1, Moscow 127473, Russian Federation

To date, the choice of treatment policy for patients with multiple myeloma (MM) is based primarily on factors, such as age and concomitant diseases. The widespread use and clinical application of cytogenetic techniques (karyotyping and fluorescence in situ hybridization (FISH)) has made it possible to identify and use cytogenetic abnormalities as prognostic biomarkers to assess key parameters, such as progression-free survival (PFS) and overall survival (OS), in patients with MM. Chromosomal abnormalities enable the identification of patients with a poor prognosis (high-risk myeloma) who have the lowest prognostic survival. Despite the clarification of the main mutations that cause a poor prognosis for survival in patients with myeloma, the question of choosing the most optimal therapy regimen to increase survival is still relevant. However, the optimal treatment has not been developed for patients with MM with high-risk cytogenetics at the time of diagnosis. With allowance made for the steadily increasing costs of managing MM patients, there is a need for their optimization just at the stage of choosing first-line therapy. The FISH assay may serve as the most rational approach to identifyng high-risk chromosomal abnormalities and to prescribing triplet therapy with new agents for these patients. The review provides brief information about the main chromosomal rearrangements occurring in MM ad their prognostic value and considers the pharmacoeconomic aspects of the treatment of patients with myeloma

Keywords: 
multiple myeloma
cytogenetic abnormalities
pharmacoeconomics
first-line therapy

References: 
  1. Cowan A.J., Allen C., Barac A. et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018; 4 (9): 1221–7. DOI:10.1001/jamaoncol.2018.2128
  2. Bianchi G., Anderson K.C. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J. Clin. 2014; 64 (6): 422–44. DOI: 10.3322/caac.21252.
  3. Morgan G.J., Johnson D.C., Weinhold N. et al. Inherited genetic susceptibility to multiple myeloma. Leukemia. 2014; 28 (3): 518–24. DOI: 10.1038/leu.2013.344.
  4. Kumar S.K., Dispenzieri A., Lacy M.Q., et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014; 28 (5): 1122–8. DOI:10.1038/leu.2013.313
  5. Rajan A.M., Rajkumar S.V. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015; 5 (10): e365. DOI:10.1038/bcj.2015.92
  6. Corre J., Munshi N., Avet-Loiseau H. Genetics of multiple myeloma: another heterogeneity level? Blood. 2015; 125 (12): 1870–6. DOI:10.1182/blood-2014-10-567370
  7. Walker B.A., Wardell C.P., Murison A. et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 2015; 6: 6997. DOI:10.1038/ncomms7997
  8. Sonneveld P., Avet-Loiseau H., Lonial S. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016; 127 (24): 2955–962. DOI: 10.1182/blood-2016-01-631200
  9. Walker B.A., Boyle E.M., Wardell C.P. et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J. Clin. Oncol. 2015; 33 (33): 3911–20. DOI: 10.1200/JCO.2014.59.1503
  10. Van de Donk N.W., Mutis T., Poddighe P.J. et al. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Int. J. Lab. Hematol. 2016; 38 (1): 110–22. DOI: 10.1111/ijlh.12504
  11. Palumbo A., Avet-Loiseau H., Oliva S. et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J. Clin. Oncol. 2015; 33 (26): 2863–9. DOI: 10.1200/JCO.2015.61.2267
  12. Bergsagel P.L., Mateos M.V., Gutierrez N.C. et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood. 2013; 121 (6): 884–92. DOI:10.1182/blood-2012-05-432203
  13. Durie B.G.M., Hoering A., Abidi M.H. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017; 389 (10068): 519–27. DOI: 10.1016/S0140-6736(16)31594-X
  14. Mateos M.V., Dimopoulos M.A., Cavo M. et al. ALCYONE Trial Investigators. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N. Engl. J. Med. 2018; 378 (6): 518–28. DOI: 10.1056/NEJMoa1714678
  15. Avet-Loiseau H., Facon T. Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. Leukemia. 2018; 32 (6): 1267–76. DOI: 10.1038/s41375-018-0098-9
  16. Rajkumar S.V., Harousseau J.L. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood. 2016; 128 (24): 2757–64. DOI: 10.1182/blood-2016-09-692947
  17. Prajs. Platnye meditsinskie uslugi. FGBU «Natsional'nyj meditsinskij issledovatel'skij tsentr gematologii» Minzdrava Rossii. [Elektronnyj resurs]. Rezhim dostupa: http: www.blood.ru (data obraschenija 9.01.2021) [Price. Paid services. National Medical Research Center for Hematology, Ministry of Health of Russia. [Electronic resource]. Access mode: http: www.blood.ru (circulation date 9.01.2021) (in Russian)].
  18. Fonseca R., Hinkel J. Value and Cost of Myeloma Therapy-We Can Afford It. Am. Soc. Clin. Oncol. Educ. Book. 2018; 38: 647–55. DOI: 10.1200/EDBK_200869
  19. Pjadushkina E.A., Bojarskaja T.V. Kliniko-ekonomicheskij analiz primenenija iksazomiba v kombinatsii s lenalidomidom i deksametazonom u vzroslyh patsientov s retsidivirujuschej ili refrakternoj mnozhestvennoj mielomoj. Meditsinskie tehnologii. Otsenka i vybor. 2018; 1 (31). [Pyadushkina E.A., Boyarskaya T.V. Clinical and economic analysis of the use of ixazomib in combination with lenalidomide and dexamethasone in adult patients with recurrent or refractory multiple myeloma. Meditsinskiye tekhnologii. Otsenka i vybor. 2018; 1 (31)